ADVAXIS INC (ADXS)
Common Stock
Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome
Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome
MONMOUTH JUNCTION, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced...
Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
AL102 is a small molecule gamma secretase inhibitor with a differentiated clinical profile
Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
Ayala Pharmaceuticals Announces AL102 Receives Orphan Drug Designation for Desmoid Tumors
Ayala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023
Ayala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023
AL102 1.2 mg once daily treatment achieved Overall Response Rate of 83% in the evaluable population AL102 1.2 mg once daily treatment resulted in 88%...
Ayala Pharmaceuticals Announces Closing of Merger with Biosight
Ayala Pharmaceuticals Announces Closing of Merger with Biosight
REHOVOT, Israel & MONMOUTH JUNCTION, N.J., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology...
Ayala Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Corporate Update
Ayala Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Corporate Update
Successful End-of-Phase 2 meeting with FDA regarding AL102 for the treatment of desmoid tumors Enrollment in the Phase 3 segment of RINGSIDE trial...
Ayala Pharmaceuticals Announces Abstracts on AL102 and AL101 Accepted for Presentation at ESMO Congress 2023
Ayala Pharmaceuticals Announces Abstracts on AL102 and AL101 Accepted for Presentation at ESMO Congress 2023
REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a publicly-traded...
Ayala Pharmaceuticals and Biosight Enter into Definitive Merger Agreement
Ayala Pharmaceuticals and Biosight Enter into Definitive Merger Agreement
Combined company to operate as Ayala Pharmaceuticals, Inc. Merger to add a clinical stage oncology asset to Ayala’s portfolio with data anticipated in...
Ayala Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA Regarding AL102 for the Treatment of Desmoid Tumors
Ayala Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA Regarding AL102 for the Treatment of Desmoid Tumors
Company confirms FDA agreement on key elements of the Phase 3 segment of ongoing RINGSIDE study, including dosing regimen of 1.2mg once daily Enrollment...
Ayala Pharmaceuticals Announces Updated RINGSIDE Phase 2 Results at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Ayala Pharmaceuticals Announces Updated RINGSIDE Phase 2 Results at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
ASCO abstract highlights 50% partial response and 100% disease control rates in evaluable desmoid tumor patients treated with AL102 1.2 mg once daily (the...
Ayala Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Corporate Update
Ayala Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Corporate Update
REHOVOT, Israel and MONMOUTH JUNCTION, N.J., May 23, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology...
Ayala Pharmaceuticals Announces RINGSIDE Results to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Poster will feature updated results from Phase 2 portion of RINGSIDE, evaluating AL102 in desmoid tumors
Ayala Pharmaceuticals Announces Continuation of RINGSIDE Phase 2/3 Study in Desmoid Tumors Following Recommendation of Independent Data Monitoring Committee
Registration-enabling Phase 3 segment of RINGSIDE is enrolling patients globally Updated data on AL102 Phase 2 segment of RINGSIDE are planned for...
Ayala Pharmaceuticals Reports Financial Results For the Fiscal Year Ended October 31, 2022
Ayala Pharmaceuticals Reports Financial Results For the Fiscal Year Ended October 31, 2022
REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Feb. 10, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (f/k/a Advaxis Inc.) (the “Company,” “New...
Advaxis and Ayala Pharmaceuticals Complete Merger
REHOVOT, Israel and WILMINGTON, Del. and MONMOUTH JUNCTION, N.J., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS), a biotechnology company...
Advaxis Updates on the Phase 1 Clinical Trial of ADXS-504 for the Treatment of Early Prostate Cancer
Dose escalation has been completed and enrollment at second dose level will be expanded at Columbia University ADXS-504 has been well tolerated with no...
Advaxis and Ayala Pharmaceuticals Enter into Merger Agreement
Merger brings U.S. management and presence, cash to develop compelling late-stage asset Lead candidate AL102 being evaluated in ongoing Phase 2/3 RINGSIDE...
Ayala Pharmaceuticals and Advaxis Enter into Merger Agreement
Advaxis Reports Third Quarter Ended July 31, 2022 Financial Results and Provides a Business Update
Announced completion of first dose level and enrollment initiation for second dose level in investigator-sponsored study of ADXS-504 in biochemically...
Advaxis Reports Second Quarter Ended April 30, 2022 Financial Results and Provides a Business Update
Announced Publication of ADXS-PSA Data in The Oncologist Presented Updated Clinical and Immunogenicity Data from Ongoing Phase 1/2 Trial of ADXS-503 in...
Advaxis, Inc. Announces 1-for-80 Reverse Stock Split
MONMOUTH JUNCTION, N.J., June 03, 2022 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS) (the “Company”), a clinical-stage biotechnology company focused on...
Advaxis to Present Updated Clinical and Immunogenicity Data from Ongoing Phase 1/2 Trial of ADXS-503 in Metastatic Non-Small-Cell Lung Cancer (NSCLC) and Study Design of ADXS-504 Trial in Early Prostate Cancer at the American Society of Clinical Oncology
Overall response rate of 14% and disease control rate of 36% in Part B of ADXS-503 trial with durable clinical benefit as an add-on therapy to patients...
Advaxis to Present at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting
MONMOUTH JUNCTION, N.J., April 27, 2022 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS), a clinical-stage biotechnology company focused on the...